Technical Analysis for SYRS - Syros Pharmaceuticals, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Fell Below 200 DMA | Bearish | 0.00% | |
| Inside Day | Range Contraction | 0.00% | |
| Gapped Down | Weakness | 0.00% | |
| Fell Below 20 DMA | Bearish | -4.46% | |
| Fell Below 50 DMA | Bearish | -4.46% | |
| MACD Bearish Signal Line Cross | Bearish | -4.46% | |
| Expansion Pivot Sell Setup | Bearish Swing Setup | -4.46% | |
| 200 DMA Support | Bullish | -4.46% | |
| Wide Range Bar | Range Expansion | -4.46% | |
| NR7 | Range Contraction | -13.96% |
| Alert | Time |
|---|---|
| Possible Inside Day | about 6 hours ago |
| 60 Minute Opening Range Breakdown | about 6 hours ago |
| Down 3% | about 6 hours ago |
| 200 DMA Resistance | about 7 hours ago |
| Gap Down Closed | about 9 hours ago |
Get a Trading Assistant
- Earnings date: 08/06/2024
Syros Pharmaceuticals, Inc. Description
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing medicines that control genes to transform the lives of patients with cancer, immune-mediated diseases, and other diseases. The company's gene control platform identifies gene control targets linked to genomically defined patient populations and drugging gene control targets; identifies potential new drug targets across a range of diseases; provides lens for diagnosing and segmenting patients, including those with complex/multi-factorial diseases; and allows users to advance a wave of medicines with the potential to influence multiple drivers of disease through a single target. Its pipeline includes SY-1425, a selective RARa agonist for genomically defined subsets of patients with relapsed or refractory acute myeloid leukemia and relapsed high-risk myelodysplastic syndrome; and SY-1365, a selective CDK7 inhibitor for acute leukemia. Syros Pharmaceuticals, Inc. was formerly known as LS22, Inc. Syros Pharmaceuticals, Inc. was founded in 2011 and is based in Cambridge, Massachusetts.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Disease Medication Acute Myeloid Leukemia Leukemia Myelodysplastic Syndrome Immune Mediated Diseases Acute Leukemia Refractory Acute Myeloid Leukemia
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 8.17 |
| 52 Week Low | 2.0902 |
| Average Volume | 112,465 |
| 200-Day Moving Average | 5.10 |
| 50-Day Moving Average | 5.28 |
| 20-Day Moving Average | 5.44 |
| 10-Day Moving Average | 5.51 |
| Average True Range | 0.33 |
| RSI (14) | 39.76 |
| ADX | 14.74 |
| +DI | 22.43 |
| -DI | 29.74 |
| Chandelier Exit (Long, 3 ATRs) | 5.14 |
| Chandelier Exit (Short, 3 ATRs) | 5.80 |
| Upper Bollinger Bands | 6.02 |
| Lower Bollinger Band | 4.85 |
| Percent B (%b) | 0.06 |
| BandWidth | 21.51 |
| MACD Line | 0.03 |
| MACD Signal Line | 0.07 |
| MACD Histogram | -0.0492 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 5.33 | ||||
| Resistance 3 (R3) | 5.36 | 5.26 | 5.26 | ||
| Resistance 2 (R2) | 5.26 | 5.16 | 5.25 | 5.24 | |
| Resistance 1 (R1) | 5.10 | 5.10 | 5.05 | 5.06 | 5.22 |
| Pivot Point | 5.00 | 5.00 | 4.97 | 4.98 | 5.00 |
| Support 1 (S1) | 4.83 | 4.90 | 4.78 | 4.80 | 4.64 |
| Support 2 (S2) | 4.73 | 4.83 | 4.72 | 4.62 | |
| Support 3 (S3) | 4.57 | 4.73 | 4.60 | ||
| Support 4 (S4) | 4.53 |
